Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
Authors
Keywords
-
Journal
Therapeutic Advances in Respiratory Disease
Volume 10, Issue 6, Pages 549-565
Publisher
SAGE Publications
Online
2016-10-27
DOI
10.1177/1753465816670498
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 456PPRECLINICAL EVIDENCE AND CLINICAL CASES OF AZD9291 ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM)
- (2017) D. Kim et al. ANNALS OF ONCOLOGY
- 1270PLEVELS OF EGFR T790M IN PLASMA DNA AS A PREDICTIVE BIOMARKER FOR RESPONSE TO AZD9291, A MUTANT-SELECTIVE EGFR KINASE INHIBITOR
- (2017) K. Thress et al. ANNALS OF ONCOLOGY
- Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
- (2016) David Planchard et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
- (2016) Yong Jia et al. CANCER RESEARCH
- LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
- (2016) S. Ramalingam et al. Journal of Thoracic Oncology
- Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer
- (2016) Haa-Na Song et al. Journal of Thoracic Oncology
- LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
- (2016) J. Yang et al. Journal of Thoracic Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Update to Rociletinib Data with the RECIST Confirmed Response Rate
- (2016) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- 425PDClinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC
- (2015) J.-S. Lee et al. ANNALS OF ONCOLOGY
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- (2015) D. Planchard et al. ANNALS OF ONCOLOGY
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
- (2015) D. Ercan et al. CLINICAL CANCER RESEARCH
- 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
- (2015) M.J. Ahn et al. EUROPEAN JOURNAL OF CANCER
- 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
- (2015) R.A. Stahel et al. EUROPEAN JOURNAL OF CANCER
- KRAS tests utilizations, biologics uptakes, and disparities in access by demographic groups among metastatic colon cancer patients.
- (2015) Daisuke Goto et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
- (2015) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
- (2015) Qingbei Zeng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
- (2015) Bin-Chi Liao et al. Journal of Thoracic Oncology
- Mechanisms of Acquired Resistance to AZD9291
- (2015) Tae Min Kim et al. Journal of Thoracic Oncology
- Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
- (2015) Petra Hoffknecht et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
- (2015) Deepa Rangachari et al. LUNG CANCER
- Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis
- (2015) Justine L. Kuiper et al. LUNG CANCER
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
- (2015) E. M. Tricker et al. Cancer Discovery
- Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
- (2015) Z. Piotrowska et al. Cancer Discovery
- Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor
- (2015) Helena A. Yu et al. JAMA Oncology
- A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib
- (2014) Karen L. Reckamp et al. CANCER
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
- (2014) Peter M Ellis et al. LANCET ONCOLOGY
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
- (2014) Hang Li et al. OncoTargets and Therapy
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
- (2013) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- (2012) Kang-Yi Su et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain
- (2011) M. Jamal-Hanjani et al. CLINICAL CANCER RESEARCH
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer
- (2010) Young Joo Lee et al. CANCER
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
- (2010) Yelena Y. Janjigian et al. Journal of Thoracic Oncology
- Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
- (2009) G. N. Naumov et al. CLINICAL CANCER RESEARCH
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now